**Patent** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Colandrea, et al.

Int'l Appln.

No. :

 $\Lambda$ 

PCT/US2004/041887

Int'l Date

Filed

13 December 2004

Serial No.:

(To be assigned)

Case No.: 21419YP

Filed

Herewith

For

(3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES

AS S1P (EDG) RECEPTOR AGONISTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Mail Stop: PCT

## PRELIMINARY AMENDMENT

Sir:

The above-identified case is a PCT application entering the U.S. National Phase under 35 U.S.C. § 371 and Article 39(1)(a) of the Patent Cooperation Treaty. Applicants respectfully request entry of the following amendments prior to prosecution of the subject application. Any additional fees associated with this Amendment may be charged to Merck Deposit Account No. 13-2755.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 38 of this paper.